Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy

Published:2022-06-07 Issue:8 Volume:15 Page:1818-1837
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Kasichayanula Sreeneeranj¹,Mandlekar Sandhya²,Shivva Vittal²,Patel Maulik³,Girish Sandhya¹

Affiliation:

1. Gilead Sciences Foster City California USA

2. Genentech South San Francisco California USA

3. AbbVie Inc. South San Francisco California USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13312

Reference105 articles.

1. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

2. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

3. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

4. Clinical Challenges of Immune Checkpoint Inhibitors

5. PD‐1/PD‐L1 pathway: current researches in cancer;Han Y;Am J Cancer Res,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies;ImmunoTargets and Therapy;2024-08

2. Characterization of CD4+ and CD8+ T cells responses in the mixed lymphocyte reaction by flow cytometry and single cell RNA sequencing;Frontiers in Immunology;2024-01-12

3. Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy;Journal of Controlled Release;2024-01

4. Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models;European Journal of Pharmacology;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3